Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00614874 · ClinicalTrials.gov registry record · Phase 2
The Use of Rosiglitazone to Treat Asthma
A Phase 2 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00614874 is a Phase 2 study that has completed, run by Creighton University. The registered enrollment target is 16 participants.
The verdict
NCT00614874, a Phase 2 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Asthma is a common chronic disease characterized by airway inflammation and bronchoconstriction. This study utilizes the drug rosiglitazone (Avandia)to treat the effects of airway inflammation in patients with asthma. The study will be conducted on 14 adult steroid naive patients with asthma. Patients with qualifying pulmonary function testing values will be eligible for enrollment. Enrolled subjects will be treated with rosiglitazone orally at 2mg dose for 4 weeks. Patients will be reassessed and dosing will increase in 4 week increments up to 8mg.
Interventions
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00614874
The ClinicalTrials.gov registry entry for NCT00614874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rosiglitazone is the first listed.
NCT00614874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00614874 about?
NCT00614874 is a clinical study titled "The Use of Rosiglitazone to Treat Asthma". Asthma is a common chronic disease characterized by airway inflammation and bronchoconstriction. This study utilizes the drug rosiglitazone (Avandia)to treat the effects of airway inflammation in patients with asthma. The study will be conducted on 14 adult steroid naive patients with asthma. Patie...
What is the current status of trial NCT00614874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2008-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00614874?
The interventions under investigation include: rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00614874?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.